The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
 
Xiaoting Wei
No Relationships to Disclose
 
Zhengyun Zou
No Relationships to Disclose
 
Weizhen Zhang
No Relationships to Disclose
 
Meiyu Fang
No Relationships to Disclose
 
Xiaoshi Zhang
No Relationships to Disclose
 
Zhiguo Luo
Research Funding - China Postdoctoral Science Foundation (I); Shanghai Anticancer Association Program
 
Jing Chen
No Relationships to Disclose
 
Gang Huang
No Relationships to Disclose
 
Peng Zhang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Jiwei Liu
No Relationships to Disclose
 
Jiyan Liu
No Relationships to Disclose
 
Junping Zhang
No Relationships to Disclose
 
Di Wu
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Xiaobiao Ma
No Relationships to Disclose
 
Hongqi Tian
Employment - Shanghai Kechow Pharma, Inc.,
 
Zhongwei Jia
Employment - Shanghai Kechow Pharma, Inc.,
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche; Shanghai Junshi BioSciences